X

 

Effective November 29, 2022, Viatris completed the sale of substantially all of its biosimilars portfolio (including related product trademarks) to Biocon Biologics Limited and its subsidiaries (“Biocon”) and the relevant marketing authorizations are in process of being transferred. Viatris Inc. and its subsidiaries (“Viatris”) are not affiliates of Biocon but are providing certain transition services to Biocon following the transaction completion date, such as operating websites (including this site) relating to the biosimilars portfolio on Biocon’s behalf.

References

  1. Burstein HJ. The Distinctive Nature of HER2-Positive Breast Cancers. N Engl J Med. 2005 Oct 20;353(16):1652-1654.
  2. Pegram M and Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol. 2000;27(suppl 9):13-19.
  3. Breastcancer.org. HER2 status. Available at: http://www.breastcancer.org/symptoms/diagnosis/her2. Updated February 17, 2017. Accessed September 19, 2019.
  4. FDA. What is a biosimilar. Available at: https://www.fda.gov/media/108905/download. Accessed on September 19, 2019.
  5. Susan G. Komen® seeks to educate patients about biosimilars. Available at: https://ww5.komen.org/News/Biosimilars7119.html. Accessed on September 19, 2019.
  6. Biosimilar basics. Available at: https:// www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars. Accessed on September 19, 2019.
  7. Ogivri Prescribing Information. Mylan Inc. September 2019.
  8. Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)–Positive metastatic breast cancer : a randomized clinical trial. JAMA. 2017;317:37-47.
  9. Breastcancer.org. Herceptin. Available at: https://www.breastcancer.org/treatment/targeted_therapies/herceptin Accessed on October 31, 2019.
  10. National Cancer Institute. Chemotherapy and you. Available at: https://www.cancer.gov/publications/patient-education/chemotherapy-and-you.pdf. Accessed May 9, 2019.
  11. Cardoso F, Bese N, Distelhorst SR, et al. Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. The Breast. 2013;22:593-605.
  12. NIH National cancer Institute. Flu-Like Symptoms Caused by Cancer Treatments. Available at: https://www.cancer.gov/about-cancer/treatment/side-effects/flu-symptoms. Accessed on October 30, 2019.
  13. Breastcancer.org. Fever. Available at: https://www.breastcancer.org/treatment/side_effects/fever. Accessed on October 30, 2019.